Current stock page

Financial Data

CLDX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

CLDXCelldex Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 7/10
$28.83+$0.30 (+1.05%)

Latest quote

  • Momentum
    48
  • Value
    —
  • Quality
    30
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$22K$15K$75K$0$730K$695K$1.18M
Gross Profit$0$22K-$839K$75K-$62.93M-$53.47M-$51.92M$356K
Operating Income-$82.25M-$80.62M-$84.44M-$87.19M-$73.62M-$63.86M-$62.74M-$56.03M
Net Income-$75.56M-$73.5M-$78.69M-$81.36M-$67.04M-$56.6M-$53.8M-$47.09M
EPS-$0.96-$0.94-$1.18-$1.23-$1.01-$0.85-$0.81-$0.71
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$65.04M-$57.41M-$65.59M-$63.94M-$48.63M-$44.01M-$54.37M-$32.48M
Capital Expenditure-$1.67M-$3.18M-$1.64M-$993K-$440K-$728K-$265K-$756K
Free Cash Flow-$66.7M-$60.59M-$67.23M-$64.93M-$49.07M-$44.73M-$54.64M-$33.23M
Net Cash Provided By Operating Activities-$65.04M-$57.41M-$65.59M-$63.94M-$48.63M-$44.01M-$54.37M-$32.48M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$721.53M$782.35M$511.25M$582.98M$648.44M$692.41M$739.47M$792.34M
Total Debt$9.87M$4.9M$1.91M$2.34M$2.62M$3.03M$3.43M$3.81M
Cash And Cash Equivalents$26.95M$47.45M$35.73M$28.87M$36.04M$23.04M$17.14M$28.36M
Total Liabilities$72.06M$67.79M$55.03M$55.82M$50.08M$37M$36.49M$45.34M
Total Stockholders Equity$649.47M$714.56M$456.23M$527.17M$598.36M$655.41M$702.98M$747.01M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.614.534.863.892.522.151.841.8
P/S ratio20,214.72———————
Debt To Equity0.020.01000000.01
Free Cash Flow Yield-11.06%-7.47%-10.19%-10.41%-12.07%-13.30%-13.29%-11.76%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.614.534.863.892.522.151.841.8
P/S ratio20,214.72———————
Return On Equity-47.59%-42.07%-62.18%-49.09%-37.52%-30.46%-25.44%-21.13%
Debt To Equity0.020.01000000.01

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-6.69x
Pb3.49x
EPS Growth Yoy4.95%
Gross Margin-662.50%
Operating Margin-298657.14%
ROE-52.67%
ROIC-50.49%
Debt To Equity0.02
FCF Yield-11.46%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$28.83
Volume544,315
RSI (14)43.46
MACD-0.57
MACD signal-0.72
MACD histogram0.15
ADX (14)17.07
SMA (50)$31.98
SMA (200)$32.84
ATR (14)$1.48
Historical volatility (annualized)54.36%
Volume (20-day average)959,027

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score55/100
Beta1.22
Annual volatility52.44%
Max Drawdown-38.65%
Sharpe Ratio0.55
VaR (95%, 1-day)-4.85%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

CLDX Financial Data FAQ

What is Celldex Therapeutics, Inc.'s revenue?

Celldex Therapeutics, Inc.'s revenue is one of the core financial data points for CLDX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Celldex Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Celldex Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is CLDX's EPS?

CLDX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Celldex Therapeutics, Inc.'s net income?

Celldex Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Celldex Therapeutics, Inc. generate?

Free cash flow shows how much cash Celldex Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Celldex Therapeutics, Inc. have?

Cash and debt help frame CLDX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.